Trial reportJournal of the American Academy of Child and Adolescent Psychiatry2012
Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study.
Trial report in Journal of the American Academy of Child and Adolescent Psychiatry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00053703 (Treatment of Schizophrenia and Related Disorders in Children and Adolescents), which is not on this map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment of Schizophrenia and Related Disorders in Children and Adolescents
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Immune and oxidative stress biomarkers in pediatric psychosis and psychosis-risk: Meta-analyses and systematic review.Brain, behavior, and immunity · 2024Pooled it
- Psychological interventions for psychosis in adolescents.The Cochrane database of systematic reviews · 2020Pooled it
- Time to Clinical Response in the Treatment of Early Onset Schizophrenia Spectrum Disorders Study.Journal of child and adolescent psychopharmacology · 2021Trial
- Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study.Journal of child and adolescent psychopharmacology · 2017Trial
- Risperidone Added to Psychostimulant in Children with Severe Aggression and Attention-Deficit/Hyperactivity Disorder: Lack of Effect on Attention and Short-Term Memory.Journal of child and adolescent psychopharmacology · 2017Trial
- Safety and Efficacy from an 8 Week Double-Blind Trial and a 26 Week Open-Label Extension of Asenapine in Adolescents with Schizophrenia.Journal of child and adolescent psychopharmacology · 2015Trial
- Quetiapine versus aripiprazole in children and adolescents with psychosis--protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial.BMC psychiatry · 2014Trial
- Neural mechanism underlying the beneficial effect of Theory of Mind psychotherapy on early-onset schizophrenia: a randomized controlled trial.Journal of psychiatry & neuroscience : JPNTrial
- Prevalence of neurocognitive deficits in patients with first-episode schizophrenia in an African sample and its relationship with dimensions of psychopathology and psychosocial outcome.BMC psychiatry · 2024Article
- Neurocognitive and social cognitive impairments in remission and symptomatic states of early-onset schizophrenia spectrum disorders.European child & adolescent psychiatry · 2023Article
- Neurodevelopment regulators miR-137 and miR-34 family as biomarkers for early and adult onset schizophrenia.NPJ schizophrenia · 2021Article
- Cognitive functioning in adolescents with schizophrenia treated with paliperidone extended-release: 6-Month exploratory analysis from an open-label, single-arm safety study.Schizophrenia research. Cognition · 2020Article
- The Effects of Combined Social Cognition and Interaction Training and Paliperidone on Early-Onset Schizophrenia.Frontiers in psychiatry · 2020Article
- Subcortical Dopamine and Cognition in Schizophrenia: Looking Beyond Psychosis in Preclinical Models.Frontiers in neuroscience · 2020Review
- Risk Model Assessment in Early-Onset and Adult-Onset Schizophrenia Using Neurological Soft Signs.Journal of clinical medicine · 2019Article
- Cross-Disorder Cognitive Impairments in Youth Referred for Neuropsychiatric Evaluation.Journal of the International Neuropsychological Society : JINS · 2018Article
- Article
- The voices go, but the song remains the same: how can we rescue cognition in early-onset schizophrenia?Journal of the American Academy of Child and Adolescent Psychiatry · 2012Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
13 authors at 7 institutions in 3 countries.
Funding
Abstract
objectiveTo assess neurocognitive outcomes following antipsychotic intervention in youth enrolled in the National Institute of Mental Health (NIMH)-funded Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS).
methodNeurocognitive functioning of youth (ages 8 to 19 years) with schizophrenia or schizoaffective disorder was evaluated in a four-site, randomized, double-blind clinical trial comparing molindone, olanzapine, and risperidone. The primary outcomes were overall group change from baseline in neurocognitive composite and six domain scores after 8 weeks and continued treatment up to 52 weeks. Age and sex were included as covariates in all analyses.
resultsOf 116 TEOSS participants, 77 (66%) had post-baseline neurocognitive data. No significant differences emerged in the neurocognitive outcomes of the three medication groups. Therefore, the three treatment groups were combined into one group to assess overall neurocognitive outcomes. Significant modest improvements were observed in the composite score and in three of six domain scores in the acute phase, and in four of six domain scores in the combined acute and maintenance phases. Partial correlation analyses revealed very few relationships among Positive and Negative Syndrome Scale (PANSS) baseline or change scores and neurocognition change scores.
conclusionsAntipsychotic intervention in youth with early-onset schizophrenia spectrum disorders (EOSS) led to modest improvement in measures of neurocognitive function. The changes in cognition were largely unrelated to baseline symptoms or symptom change. Small treatment effect sizes, easily accounted for by practice effects, highlight the critical need for the development of more efficacious interventions for the enduring neurocognitive deficits seen in EOSS. Clinical trial registry information-Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS); http://www.clinicaltrials.gov; NCT00053703.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.